Baxter’s BioPharma Solutions business has completed its latest capacity expansion at its cytotoxic contract manufacturing facility in Halle/Westfalen, Germany. The expansion included the installation of an additional large-scale, commercial lyophilization unit to increase freeze-drying capacity to support commercial cytotoxic manufacturing capacity. The freeze dryer was designed to meet international manufacturing and regulatory requirements.

“This latest investment clearly demonstrates our commitment to meeting our clients’ increasing need for high-quality, cytotoxic drug production,” said Dr. Burkhard Wichert, vice president of manufacturing for Baxter’s Halle facility. “The expansion, which was completed ahead of schedule, will help support the continuous worldwide supply of oncology products for our customers and, ultimately, for patients who are afflicted with cancer.”

The Halle manufacturing site provides lyophilization, process development, aseptic filling of cytotoxic, non-cytotoxic and highly potent liquid and sterile powder vials in clinical and commercial batch sizes, and sterile crystallization of cytotoxic APIs.